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Discoveries of Nicotinamide Riboside as a Nutrient
and Conserved NRK Genes Establish a Preiss-Handler
Independent Route to NAD in Fungi and Humans
(Maayan, 1964). In 2000, it became clear that Sir2 and
Sir2-related enzymes termed Sirtuins deacetylate lysine
residues with consumption of an equivalent of NAD
and that this activity is required for Sir2 function as a
transcriptional silencer (Imai et al., 2000). It was also
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Lebanon, New Hampshire 03756 demonstrated that the Preiss-Handler pathway is re-
quired for normal silencing activity in vivo (Smith et al.,
2000). NAD-dependent deacetylation reactions are re-
quired not only for alterations in gene expression butSummary
also for repression of ribosomal DNA recombination and
extension of lifespan in response to calorie restrictionNAD is essential for life in all organisms, both as
a coenzyme for oxidoreductases and as a source of (Lin et al., 2000, 2002). NAD is consumed by Sir2 to
produce a mixture of 2- and 3O-acetylated ADPriboseADPribosyl groups used in various reactions, including
those that retard aging in experimental systems. Nico- plus nicotinamide and the deacetylated polypeptide
(Sauve et al., 2001). Additional enzymes, including polytinic acid and nicotinamide were defined as the vitamin
precursors of NAD in Elvehjem’s classic discoveries (ADPribose) polymerases and cADPribose synthases
are also NAD-dependent and produce nicotinamideof the 1930s. The accepted view of eukaryotic NAD
biosynthesis, that all anabolism flows through nico- and ADPribosyl products (Ziegler, 2000; Burkle, 2001).
Interest in the noncoenzymatic properties of NADtinic acid mononucleotide, was challenged experi-
mentally and revealed that nicotinamide riboside is an has rekindled interest in NAD biosynthesis. In the last
two years, at least five publications have schematizedunanticipated NAD precursor in yeast. Nicotinamide
riboside kinases from yeast and humans essential for NAD biosynthesis in yeast as shown in Figure 1 (Pa-
nozzo et al., 2002; Sandmeier et al., 2002; Bitterman etthis pathway were identified and found to be highly
specific for phosphorylation of nicotinamide riboside al., 2002; Anderson et al., 2003; Gallo et al., 2004). This
scheme depicts a convergence of the flux to NAD fromand the cancer drug tiazofurin. Nicotinamide riboside
was discovered as a nutrient in milk, suggesting that de novo synthesis, nicotinic acid import, and nicotin-
amide salvage at NaMN. This is somewhat surprisingnicotinamide riboside is a useful compound for eleva-
tion of NAD levels in humans. because biochemists from 1950 to the present day have
been characterizing the Nma1 and Nma2 gene products
from yeast and their human homologs as NMN adenylyl-Introduction
transferases (Kornberg, 1950; Emanuelli et al., 1999,
2003; Garavaglia et al., 2002) or as dual specificity en-In 1938, the pioneering vitamin-hunter Conrad Elvehjem
and his coworkers put dogs on a synthetic diet supple- zymes that will use either NaMN or NMN as a substrate
(Zhou et al., 2002).mented with only the known B vitamins. When the dogs
were near death and exhibited pellagra-like black In this study, we show that nicotinamide riboside,
which was known to be an NAD precursor in bacteriatongue symptoms, the investigators fed the animals
small-molecule fractions derived from liver. In this man- such as Haemophilus influenza (Gingrich and Schlenk,
1944; Leder and Handler, 1951; Shifrine and Biberstein,ner, nicotinic acid and nicotinamide, now collectively
termed niacin, were identified as the “anti-black tongue 1960) that lack the enzymes of the de novo and Preiss-
Handler pathways (Fleischmann et al., 1995), is an NADfactor” with essential nutritional activity (Elvehjem et al.,
1938). Because niacins are the vitamin forms of nicotin- precursor in a previously unknown but apparently con-
served eukaryotic NAD biosynthetic pathway. We iden-amide adenine dinucleotide (NAD), and eukaryotes
also synthesize NAD de novo via the kynurenine path- tify yeast nicotinamide riboside kinase, Nrk1, and both
human Nrk enzymes and demonstrate their specificway from tryptophan (Krehl et al., 1945; Schutz and
Feigelson, 1972), niacin supplementation prevents the functions in NAD metabolism biochemically and genet-
ically. Their specificity suggests additionally that theypellagra that can occur in populations with a trypto-
phan-poor diet. In 1958, Jack Preiss and Philip Handler are the long-sought tiazofurin kinases that perform the
first step in converting cancer drugs such as tiazofurindetermined that nicotinic acid is phosphoribosylated to
nicotinic acid mononucleotide (NaMN), which is then and benzamide riboside into toxic NAD analogs
(Cooney et al., 1983). Finally, we utilize yeast mutantsadenylylated to form nicotinic acid adenine dinucleotide
(NaAD), which in turn is amidated to form NAD (Preiss of defined genotype to hunt for vitamins in a pathway-
specific manner and show that milk is a source of nico-and Handler, 1958a, 1958b).
NAD was initially characterized as a coenzyme for tinamide riboside.
oxidoreductases. Though conversions between NAD,
NADH, NADP, and NADPH would not be accompanied Results
by a loss of total coenzyme, it was discovered that NAD
is also turned over in cells for unknown purposes Recently, we characterized the S. cerevisiae QNS1 gene
encoding glutamine-dependent NAD synthetase and
showed that mutation of either the glutaminase active*Correspondence: charles.brenner@dartmouth.edu
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Figure 1. Three Known Biosynthetic Routes
to NAD in S. cerevisiae
NAD is synthesized from the de novo kynur-
enine pathway that originates with trypto-
phan using the Bna1-Bna6 gene products, an
import pathway that originates with nicotinic
acid, and a salvage pathway that utilizes nico-
tinamide produced as a function of Sir2-
related lysine deacetylases. According to
this scheme, nicotinic acid mononucleotide
(NaMN) is common to all three pathways and
Qns1, the glutamine-dependent NAD syn-
thetase that converts nicotinic acid adenine
dinucleotide (NaAD) to nicotinamide adenine
dinucleotide (NAD), is required for all path-
ways (Panozzo et al., 2002; Sandmeier et al.,
2002; Bitterman et al., 2002; Anderson et al.,
2003; Gallo et al., 2004). Note that Nma1 and
Nma2 are schematized as NaMN adenylyl-
transferases, though they were initially char-
acterized as nicotinamide mononucleotide
(NMN) adenylyltransferases (Kornberg, 1950;
Emanuelli et al., 1999, 2003).
site or the NAD synthetase active site resulted in invia-
ble cells (Bieganowski et al., 2003). Possession of strains
containing the qns1 deletion and a plasmid-borne QNS1
gene allowed us to test whether the canonical de novo,
import, and salvage pathways for NAD as depicted in
Figure 1 (Panozzo et al., 2002; Sandmeier et al., 2002;
Bitterman et al., 2002; Anderson et al., 2003; Gallo et
al., 2004) are a complete representation of the metabolic
pathways to NAD in S. cerevisiae. This scheme makes
two specific predictions. First, because nicotinamide is
deamidated to nicotinic acid before the pyridine ring is
salvaged to make more NAD, supplementation with
nicotinamide should not rescue qns1 mutants by
shunting nicotinamide-containing precursors through
the pathway. Second, because QNS1 is common to the
three pathways, there should be no NAD precursor that
rescues qns1 mutants. As shown in Figure 2A, consis-
tent with the scheme’s implicit assumptions about nico-
tinamide metabolism, nicotinamide does not rescue
qns1 mutants even at 1 or 10 mM. However, apart from
any intermediate or enzymatic transformation depicted
in the scheme, nicotinamide riboside, which was charac-
terized as an NAD precursor in bacteria such as
Haemophilus influenza (Gingrich and Schlenk, 1944;
Leder and Handler, 1951; Shifrine and Biberstein, 1960),
functions as a vitamin form of NAD at 10 M.
Two independent lines of evidence suggest that a
pathway to NAD from nicotinamide riboside may exist
in fungi and other eukaryotes. First, though the recent
literature (Panozzo et al., 2002; Sandmeier et al., 2002;
Bitterman et al., 2002; Anderson et al., 2003; Gallo et
al., 2004) depicts all of the metabolic flux through NaMN, Figure 2. Nicotinamide Riboside Allows NADSynthetase-Indepen-
the enzymes placed on this scheme as NaMN adenylyl- dent Growth Via a Novel Pathway
transferases were initially classified as NMN adenylyl- (A) qns1 cells transformed with a plasmid carrying the QNS1 and
URA3 genes were tested for growth on synthetic dextrose completetransferases (Kornberg, 1950; Emanuelli et al., 1999,
media and 5-fluoroorotic acid (5-FOA). NAD synthetase mutant2003; Garavaglia et al., 2002) or as dual specificity NMN/
qns1 is inviable without supplements or with 1 mM nicotinamideNaMN adenylyltransferases (Zhou et al., 2002). Though
but is rescued by 10 M nicotinamide riboside.it is possible that eukaryotic adenylyltransferases were
(B) Strains with indicated mutations were plated on medium supple-
misclassified, it is reasonable to ask whether eukaryotes mented with 5-FOA and 10 M nicotinamide riboside. Deletion of
have a pathway that produces NMN to feed into these genes for uridine/cytosine kinase, adenosine kinase, and ribokinase
do not alter the ability of yeast cells to utilize nicotinamide riboside.enzymes.
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been established (Zhou et al., 2002), several different
enzymes including adenosine kinase, 5 nucleotidase
(Fridland et al., 1986; Saunders et al., 1990) and a spe-
cific nicotinamide riboside kinase (Saunders et al., 1990)
have been proposed to be responsible for tiazofurin
phosphorylation in vivo. Indeed, a putative nicotinamide
riboside kinase (Nrk) activity was reportedly purified but
no amino acid sequence information was obtained and,
as a consequence, no genetic test was ever performed
to assess its function in nutrient or drug metabolism
(Sasiak and Saunders, 1996).
To test whether any of the nucleoside kinases pro-
posed to phosphorylate tiazofurin are uniquely or collec-
tively responsible for utilization of nicotinamide riboside,
we prepared a qns1 deletion strain that was additionally
deleted for all of the candidate genes for which yeast
homologs exist, namely adenosine kinase ado1 (Lecoq
et al., 2001), uridine/cytidine kinase urk1 (Kern, 1990;
Kurtz et al., 1999), and ribokinase rbk1 (Thierry et al.,
1990). As shown in Figure 2B, despite these deletions,
the strain retained the ability to utilize nicotinamide ribo-
side in an anabolic pathway independent of NAD syn-
thetase. Given that mammalian pharmacology provided
no useful clue to the identity of a putative fungal Nrk,
we considered whether the gene might have been con-
served with the Nrk of H. influenza. The Nrk domain of
H. influenza is encoded by amino acids 225 to 421 of
the NadR gene product (the amino terminus of which is
NMN adenylyltransferase). Though this domain is struc-
turally similar to yeast thymidylate kinase (Singh et al.,
2002), sensitive sequence searches (not shown) re-
vealed that bacterial Nrk has no ortholog in yeast. In-
deed, genomic searches with the Nrk domain of H. influ-
enza NadR have identified a growing list of bacterial
genomes predicted to utilize nicotinamide riboside as
an NAD precursor (Kurnasov et al., 2002). Thus, had
fungi possessed NadR Nrk-homologous domains, com-
parative genomics would have already predicted that
yeast can salvage nicotinamide riboside.
To identify the Nrk of S. cerevisiae, we established an
HPLC assay for the enzymatic activity and utilized a
Figure 3. Nicotinamide Riboside and its Analogs, Tiazofurin and biochemical genomics approach to screen for the gene
Benzamide Riboside encoding this activity (Martzen et al., 1999). Sixty-four
Nicotinamide riboside, first reported as the lowest molecular weight pools of 90–96 S. cerevisiae open reading frames fused
“V factor” for Haemophilus influenza (Gingrich and Schlenk, 1944),
to glutathione S-transferase (GST), expressed in S. cere-is shown alongside the IMP dehydrogenase prodrugs, tiazofurin
visiae, were purified as GST fusions and screened for(Cooney et al., 1983), and benzamide riboside (Krohn et al., 1992).
the ability to convert nicotinamide riboside plus ATP toNMN and its analogs are produced via phosphorylation of the 5
hydroxyl groups. NMN plus ADP. As shown in Figure 4A, whereas most
pools contained activities that consumed some of the
input ATP, only pool 37 consumed nicotinamide riboside
Second, anticancer agents such as tiazofurin (Cooney and produced NMN. Examination of the 94 open reading
et al., 1983) and benzamide riboside (Krohn et al., 1992) frames that were used to generate pool 37 revealed that
have been shown to be metabolized intracellularly to YNL129W encodes a predicted 240 amino acid polypep-
NAD analogs tiazofurin adenine dinucleotide and ben- tide with a 187 amino acid segment containing 23%
zamide adenine dinucleotide, which inhibit IMP de- identity with the 501 amino acid yeast uridine/cytidine
hydrogenase, the rate-limiting enzyme for guanine nu- kinase Urk1 and remote similarity with a segment of
cleotide biosynthesis. As these compounds can be E. coli pantothenate kinase panK (Yun et al., 2000) (Fig-
considered analogs of nicotinamide riboside (Figure 3), ure 4B). Cloning of YNL129W into a bacterial expression
generation of NAD analogs would necessarily involve vector allowed us to test the hypothesis that this homo-
phosphorylation of the 5 hydroxyl group and subse- log of metabolite kinases is the eukaryotic Nrk. Strik-
quent adenylylation of these intermediates. Though an ingly, the specific activity of purified YNL129W was
NMN/NaMN adenylytransferase is thought to be the en- 100 times that of pool 37, consistent with the idea that
zyme that converts the mononucleotide intermediates all the Nrk activity of pool 37 was encoded by this open
reading frame. To test genetically whether this geneto NAD analogs and the structural basis for this has
Cell
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Figure 4. Cloning and Genetic Validation of Yeast and Human Nicotinamide Riboside Kinases
(A) HPLC traces of a negative pool (36) and positive pool (37) of GST-ORF fusions. In pool 36, some ATP was converted to ADP and production
of AMP occurred in several pools including 37. In pool 37, approximately half of the 1 mM ATP was converted to ADP and the 500 M Nr
peak was almost entirely converted to NMN.
(B) Amino acid sequence alignment of human Nrk1, human Nrk2, S. cerevisiae Nrk1, S. pombe nrk1, and portions of S. cerevisiae uridine/
cytidine kinase Urk1 and E. coli pantothenate kinase.
(C) nrk1 deletion introduced into a qns1 deletion strain blocks the ability to form colonies in the presence of nicotinamide riboside. Expression
of human NRK1 or human NRK2 cDNAs restores growth to qns1 nrk1 deletion strains, indicating that human Nrk1 and Nrk2 are authentic
nicotinamide riboside kinases in vivo.
product phosphorylates nicotinamide riboside in vivo, a second human gene product Nrk2 (locus NP_733778)
that is 57% identical to human Nrk1. Nrk2 is a 230 aminowe created a deletion of YNL129W in the qns1 back-
ground and found that nicotinamide riboside rescue of acid splice form of what was described as a 186 amino
acid muscle integrin 1 binding protein (ITGB1BP3) en-the qns1 deletion strain is entirely dependent on this
gene product (Figure 4C). Having shown biochemically coded at 19p13.3 (Li et al., 1999, 2003). Amino acid
conservation between S. cerevisiae, S. pombe, and hu-and genetically that YNL129W encodes an authentic Nrk
activity, we named this gene NRK1. man Nrk homologs and similarity with fragments of
S. cerevisiae Urk1 and E. coli panK is shown in FigureWe ran PSI-BLAST (Altschul et al., 1997) on the pre-
dicted S. cerevisiae Nrk1 polypeptide and discovered 4B. As shown in Figure 4C, complementation of the
failure of qns1 nrk1 to grow on nicotinamide riboside-the apparent orthologous human protein Nrk1 (locus
NP_060351) encoded at 9q21.31, encoding a polypep- supplemented media was provided by human NRK1 and
human NRK2 cDNAs expressed from the yeast GAL1tide of 199 amino acids annotated as an uncharacterized
protein of the uridine kinase family. In addition, we found promoter.
Table 1. Specific Activity (nmole mg1 min1) of human Nrk1, Nrk2, and yeast Nrk1 for Phosphorylation of Nucleoside Substrates
Nicotinamide riboside Tiazofurin Uridine Cytidine
Human Nrk1 275  177 538  277 19.3  1.77 35.5  6.44
Human Nrk2 2320  200 2150  2100 2220  170 222  88
Yeast Nrk1 535  600 1129  1344 15.2  3.44 82.9  4.44
Eukaryotic Nicotinamide Riboside Kinase Pathway
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side kinase for growth, the nutrient is clearly nicotin-
amide riboside and not NMN or NAD.
Discussion
A revised metabolic scheme for NAD, incorporating
Nrk1 homologs and the nicotinamide riboside salvage
pathway is shown in Figure 6. A little appreciated dif-
ference between humans and yeasts concerns the or-
ganisms’ uses of nicotinamide and nicotinic acid, the
compounds coidentified as anti black tongue factor (El-Figure 5. Nicotinamide Riboside Is Present in an Acid Whey Vitamin
vehjem et al., 1938). Humans encode a homolog of theFraction of Cow’s Milk
Haemophilus ducreyi nadV gene, termed pre-B-cell col-Yeast qns1 mutants grow when supplemented with whey in an
ony enhancing factor, that may convert nicotinamide toNRK1-dependent manner, indicating that whey is a source of nico-
tinamide riboside. NMN (Rongvaux et al., 2002), which is highly induced
during lymphocyte activation (Samal et al., 1994). In con-
trast, S. cerevisiae lacks a homolog of nadV and instead
has a homolog of the E. coli pncA gene, termed PNC1,Purification of yeast Nrk1 and human Nrk1 and Nrk2
revealed high specificity for phosphorylation of nicotin- that converts nicotinamide to nicotinic acid for entry
into the Preiss-Handler pathway (Ghislain et al., 2002;amide riboside and tiazofurin (Table 1). In the cases
of yeast and human Nrk1, the enzymes actually prefer Sandmeier et al., 2002). Though the Preiss-Handler path-
way is frequently considered a salvage pathway fromtiazofurin to the natural substrate nicotinamide riboside
by a factor of two and both enzymes retain less than nicotinamide, it technically refers to the steps from nico-
tinic acid to NAD (Preiss and Handler, 1958a, 1958b).7% of their maximal specific activity on uridine and cyti-
dine. In the case of human Nrk2, the 186 amino acid Reports that nicotinamidase had been purified from
mammalian liver in the 1960s (Petrack et al., 1965) mayintegrin 1 binding protein form is devoid of enzymatic
activity (data not shown). On the other hand, the 230 have contributed to the sense that fungal and animal
NAD biosynthesis is entirely conserved. However, ani-amino acid form is essentially equally active on nicotin-
amide riboside, tiazofurin, and uridine with less than mal genes for nicotinamidase have not been identified
and there is no compelling evidence that nicotinamide10% of corresponding activity on cytidine. Thus, though
Nrk2 may contribute additionally to formation of uridy- and nicotinic acid are utilized as NAD precursors
through the same route in mammals. The persistencelate in the tissues in which it is expressed, these data
demonstrate that fungi and mammals possess specific of “niacin” as a mixture of nicotinamide and nicotinic
acid may attest to the utility of utilizing multiple path-Nrks that function to synthesize NAD through NMN in
addition to the well-known pathways through NaMN. ways to generate NAD and suggests that supplementa-
tion with nicotinamide riboside as third importable NADIdentification of Nrk enzymatic activities thus accounts
for the dual specificity of fungal and mammalian NaMN/ precursor may be beneficial for certain conditions.
Whereas nicotinamide metabolism is not conservedNMN adenylyltransferases.
We used the yeast qns1 mutant to screen for natural between vertebrates and fungi, presence of NRK genes
suggests that the nicotinamide riboside kinase pathwaysources of nicotinamide riboside and, as shown in Fig-
ure 5, we found it in a vitamin fraction of cow’s milk. is conserved more broadly in eukaryotes, though it is
likely to be time and tissue-restricted in animals.Unlike the original screen for vitamins in protein-depleted
extracts of liver for reversal of black tongue in starving First reported in 1955, high doses of nicotinic acid are
effective at reducing cholesterol levels (Altschul et al.,dogs (Elvehjem et al., 1938), this assay is pathway-spe-
cific in identifying NAD precursors. As shown in Figures 1955). Since the initial report, many controlled clinical
studies have shown that nicotinic acid preparations,1 and 2, because of the qns1 deletion, nicotinic acid
and nicotinamide do not score positively in this assay. alone and in combination with HMG co-A reductase
inhibitors, are effective in controlling low-density lipo-Because the factor from milk requires nicotinamide ribo-
Figure 6. NAD Metabolism in Humans and
Yeast
A revised scheme for NAD metabolism in
which double arrows depict steps common to
yeast and humans (with yeast gene names).
Single arrows depict steps unique to humans
(PBEF, nicotinamide phosphoribosyltransfer-
ase) and yeast (Pnc1, nicotinamidase). Addi-
tional gene products are responsible for
some of the steps. For example, there are
multiple Sir2-related lysine deacetylases in
humans and yeast and additional NAD glycohydrolases in humans along the arrow marked Sir2, and there are two Nrk enzymes in humans
along the arrow marked Nrk1. The scheme remains incomplete in that there are enzyme and E.C. names for some additional possible steps
in NAD biosynthesis, particularly for breakdown of NAD to nicotinamide riboside (Magni et al., 2004), that have not been genetically validated.
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of commercial nonfat cow’s milk was prepared by adjusting the pHprotein cholesterol, increasing high-density lipoprotein
to 4 with HCl, stirring at 55C for 10 min, removal of denaturedcholesterol, and reducing triglyceride and lipoprotein a
casein by centrifugation, and passage through a 5000 Da filter. Inlevels in humans (Pasternak et al., 1996). Though nico-
yeast media, nicotinamide riboside was used at 10 M and whey
tinic acid treatment effects all of the key lipids in the vitamin fraction at 50% by volume.
desirable direction and has been shown to reduce mor-
tality in target populations (Pasternak et al., 1996), its use Yeast GST-ORF Library
Preparation of the fusion protein library was as described (Martzenis limited because of a side effect of heat and redness
et al., 1999; Phizicky et al., 2002) at a 500 ml culture scale for eachtermed “flushing,” which is significantly effected by the
of the 64 pools of 90–96 protein constructs. 10% of each poolnature of formulation (Capuzzi et al., 2000). Thus, it will
preparation was assayed for Nrk activity in overnight incubations.be important to test whether nicotinamide riboside sup-
plementation is a preferred route to improve lipid profiles Nicotinamide Riboside Phosphorylation Assays
in humans. Additionally, study of the expression and Reactions (0.2 ml), containing 100 mM NaCl, 20 mM Na HEPES [pH
regulation of NAD biosynthetic enzymes is expected 7.2], 5 mM -mercaptoethanol, 1 mM ATP, 5 mM MgCl2, and 500 M
nicotinamide riboside or alternate nucleoside were incubated atto reveal approaches to sensitize tumors to compounds
30C and terminated by addition of EDTA to 20 mM and heating forsuch as tiazofurin, to protect normal tissues from the
2 min at 100C. Specific activity assays, containing 50 ng to 6 gtoxicity of compounds such as tiazofurin adenine dinu-
enzyme depending on the enzyme and substrate, were incubatedcleotide, and to stratify patients for the most judicious for 30 min at 30C to maintain initial rate conditions. Reaction prod-
use of tiazofurin chemotherapy. ucts were analyzed by HPLC on a strong anion exchange column
with a 10 mM to 750 mM gradient of KPO4 [pH 2.6].
Experimental Procedures
NRK Gene and cDNA Cloning and Enzyme Purification
S. cerevisiae Strains The S. cerevisiae NRK1 gene was amplified from total yeast DNA
Yeast diploid strain BY165, heterozygous for qns1 deletion and hap- with primers 7448 and 7449. The amplified DNA fragment was cloned
loid BY165-1d carrying a chromosomal deletion of qns1 gene, trans- in vector pSGA04 (Ghosh and Lowenstein, 1997) for E. coli expres-
formed with plasmid pB175 containing QNS1 and URA3 were de- sion using restriction sites for NdeI and XhoI included in primer
scribed previously (Bieganowski et al., 2003). Genetic deletions were sequences and the resulting plasmid was named pB446. Samples
introduced by direct transformation with PCR products (Brachmann of cDNA made from human lymphocytes and spleen were used as
et al., 1998) generated from primers listed in Supplemental Data a template for amplification of human NRK1 performed with primers
available at http://www.cell.com/cgi/content/full/117/4/495/DC1. 4754 and 4755. Plasmid pB449 was created by cloning of the prod-
Plating on media containing 5-fluoroorotic acid (Boeke et al., 1987) uct of this reaction between restriction sites NcoI and BamHI of
was after growth for 24 hr on complete media. The ado1 disruption vector pMR103 (Munson et al., 1994) for E. coli expression. Plasmid
cassette was constructed by PCR with primers 7041 and 7044 and pB449 was used as a template for PCR reaction with primers 7769
plasmid pRS413 as a template. Yeast strain BY165 was transformed and 7770. The product of this amplification was cloned between
with this PCR product, and homologous recombination in histidine BamHI and XhoI sites of vector p425GAL1 (Mumberg et al., 1994)
prototrophic transformants was confirmed by PCR with primers and the resulting plasmid carrying human NRK1 gene under GAL1
7042 and 7043. This strain was transformed with plasmid pB175 and promoter control was named pB450. Human NRK2 cDNA was ampli-
subjected to sporulation and tetrad dissection. One of the resulting fied with primers 7777 and 7776. The amplified fragment was di-
haploids carrying qns1 and ado1 deletions and plasmid was se- gested with NdeI and XhoI enzymes and cloned in plasmid pSGA04
lected for further experiments and named BY237. The urk1 deletion for E. coli expression (pB457) and into plasmid p425GAL1 for yeast
was introduced into strain BY237 by transformation with the product expression (pB459). His-tagged enzymes were purified by immobi-
of the PCR amplification that used pRS415 as a template and prim- lized cobalt affinity chromatography (Becton Dickenson).
ers 7051 and 7052. Disruption was confirmed by PCR with primers
7053 and 7054, and the resulting strain was named BY247. The rbk1 Acknowledgments
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